[{"abstract": "The deal will give Merck, the second-largest American drug maker after Pfizer, control of the largest antibiotics company, and deepen its ties with hospitals.", "web_url": "https://dealbook.nytimes.com/2014/12/08/merck-agrees-to-acquire-drug-maker-cubist-for-9-5-billion/", "snippet": "The deal will give Merck, the second-largest American drug maker after Pfizer, control of the largest antibiotics company, and deepen its ties with hospitals.", "lead_paragraph": "Deal making in the health care industry has been booming all year, with medical technology companies and cosmetic drug makers changing hands at rich premiums.", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/12/09/business/Drug/Drug-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/12/09/business/Drug/Drug-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/12/09/business/Drug/Drug-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/12/09/business/Drug/Drug-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/12/09/business/Drug/Drug-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/12/09/business/Drug/Drug-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/12/09/business/Drug/Drug-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Merck in $8.4 Billion Deal for Cubist, Big Maker of Antibiotics", "kicker": "DealBook", "content_kicker": null, "print_headline": "Merck in Deal for Big Maker of Antibiotics", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Biotechnology and Bioengineering", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Cubist Pharmaceuticals Inc", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Merck & Company Inc", "rank": 5, "major": "N"}], "pub_date": "2014-12-08T12:53:59+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By David Gelles", "person": [{"firstname": "David", "middlename": null, "lastname": "Gelles", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/d7ab937e-c988-5d8e-a3ba-2a9d72be2698", "word_count": 970, "uri": "nyt://article/d7ab937e-c988-5d8e-a3ba-2a9d72be2698"}, {"abstract": "Merck agrees to buy Cubist in a deal valued at $9.5 billion. | A hedge fund keeps an S.E.C. inquiry quiet. | Big deals are back this year. | Deal makers regain their power on Wall Street.", "web_url": "https://dealbook.nytimes.com/2014/12/08/morning-agenda-merck-goes-after-cubist/", "snippet": "Merck agrees to buy Cubist in a deal valued at $9.5 billion. | A hedge fund keeps an S.E.C. inquiry quiet. | Big deals are back this year. | Deal makers regain their power on Wall Street.", "lead_paragraph": "The big drug maker Merck & Company announced on Monday that it had agreed to buy Cubist Pharmaceuticals for $9.5 billion, including debt, Merck said in a statement. Under the terms of the agreement, Merck will acquire Cubist for $102 a share in cash, or 35 percent above Cubist\u2019s average stock price over the last five trading days, Merck said.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Morning Agenda: Merck Goes After Cubist", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2014-12-08T13:17:56+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Sydney Ember", "person": [{"firstname": "Sydney", "middlename": null, "lastname": "Ember", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/c08b8cc1-6557-5ed8-8f51-e4be3839db61", "word_count": 2239, "uri": "nyt://article/c08b8cc1-6557-5ed8-8f51-e4be3839db61"}, {"abstract": "Merck is paying only about 4.3 times Cubist\u2019s estimated revenue for next year \u2014 about the same multiple investors give Merck itself, making the acquisition look like a relative bargain, writes Robert Cyran of Reuters Breakingviews.", "web_url": "https://dealbook.nytimes.com/2014/12/08/revival-for-antibiotics-could-spur-deals/", "snippet": "Merck is paying only about 4.3 times Cubist\u2019s estimated revenue for next year \u2014 about the same multiple investors give Merck itself, making the acquisition look like a relative bargain, writes Robert Cyran of Reuters Breakingviews.", "lead_paragraph": "Superbugs may have beneficial side effects \u2013 for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck is betting $8.4 billion that the antibiotics used to fight them will become more profitable.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/12/09/business/dbpix-merck/dbpix-merck-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/12/09/business/dbpix-merck/dbpix-merck-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/12/09/business/dbpix-merck/dbpix-merck-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/12/09/business/dbpix-merck/dbpix-merck-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/12/09/business/dbpix-merck/dbpix-merck-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/12/09/business/dbpix-merck/dbpix-merck-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/12/09/business/dbpix-merck/dbpix-merck-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Revival for Antibiotics Could Spur Deals", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "ANTIBIOTICS", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Cubist Pharmaceuticals Inc", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Merck & Company Inc", "rank": 5, "major": "N"}], "pub_date": "2014-12-08T19:39:29+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/31c7ecfb-55f6-5a0e-920a-74533c0228df", "word_count": 378, "uri": "nyt://article/31c7ecfb-55f6-5a0e-920a-74533c0228df"}]